Good NICE news for Pfizer, but Dendreon drug rejected pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Sovaldi stumbles as NICE assesses hep C drug s price
Gilead must provide much more cost-effectiveness information
The UK has become the latest country to put the price of Sovaldi under the microscope and Gilead s hepatitis C drug has stumbled at its first hurdle.
In draft guidance the cost-effectiveness watchdog NICE said it was “minded not to recommend” Sovaldi (sofobuvir), adding that it has asked the drug s manufacturer for much more detailed information about its use and cost.
The first all-oral treatment for chronic hep C to be approved in Europe, Sovaldi is taken for an average of 12 or 24 weeks, depending on patient needs, giving it a UK list price of £35,983 (€45,041) or £69,966 (€87,575) for a course of treatment.